Document:

Exhibit 10.178

 

CONSULTING AGREEMENT

 

 

THIS CONSULTING AGREEMENT
(the “Agreement”) is made and entered into by and between VG LIFE SCIENCES INC., a Delaware corporation (the “Client”),
and Sanjib Mukherjee (“Consultant”) effective the 10th day of August, 2015.

 

(the Client and Consultant are jointly referred
to herein as the “Parties”)

 

WHEREAS, Client
is engaged in the business of researching, developing and distributing products and technology with applications in Life Sciences,
including but not limited to treating autoimmune disease, treating cancer, biofuel and agricultural oil production; and

 

WHEREAS, Consultant has been engaged
in and has experience in the Client’s business; and

 

WHEREAS, the Client desires to provide
for the engagement of Consultant, to clearly set forth the relationship between the parties, and to restrict Consultant from using
certain confidential information and from competing with the Client in the future.

 

NOW THEREFORE, for
good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows.

 

1) Non-Exclusive
Engagement of Consultant; Term. The Client hereby engages Consultant as its non-exclusive provider of the consulting services
described in this Agreement, for a term (the “Term”) which will commence on the date of this Agreement and continue
on a month-to-month basis or terminated as described in Section 11.

 

2)
Consultant Services. On the terms and conditions set forth in this Agreement, Consultant will provide the following services
to the Client as directed by the Client (the “Services”).  

		a)	Consultant will assist in the compilation, organization, gathering,
ordering, filing and archiving of data, lab results, white papers, and other information generated in its research including that
conducted, directed or designed by M. Karen Newell-Rogers, or contracted vendors to aid in the creation of a restricted access
“data room” for Client information concerning its products and test results; and

		b)	Consultant will assist and advise the Client in press releases
and other areas in which Consultant has expertise as reasonably requested from time to time by the Client.

 

3) Method
of Providing Services. Consultant shall be available to the management of the Client as reasonably requested during the Term.
Consultant will perform Services, and may communicate with the Client’s management and other parties, through personal meetings,
correspondence, telephone or video conferences, and such other methods, and at such times, as mutually determined, subject to the
reasonable convenience of the parties. Unless requested otherwise by the Client, Consultant shall communicate with the Client’s
management through the Client’s CEO or VP of Intellectual Property. Acting in good faith and consistent with ordinary business
practices with respect to advisory relationships, Consultant shall devote a reasonable amount of time per month to the provision
of the Services described herein provided that this does not materially conflict with Consultant’s appointment at Institution.

 

4)
Performance. Consultant agrees to at all times faithfully, industriously, and to the reasonable best of his or her abilities,
experience, and talents, perform all of the Services that may be required of and from him or her pursuant to the express and explicit
terms hereof.

    	1

     

    

 

5) Independence
of Parties. Nothing contained in this Agreement shall constitute either party as an employee, partner, co-venturer or agent
of the other, it being intended that each shall act as an independent contractor with respect to the other. Consultant is not authorized
to speak on behalf of the Client or bind it in any manner. 

 

6) Compensation.

		a)	Fee: $3,500 per month. The monthly fee will consist of $2,000
in cash payment and $1,500 in common stock. Common stock will be priced at the monthly volume weighted average price for each month
accrued. Stock will be issued quarterly. 

 

7) Client
Representations and Warranties. The Client hereby represents and warrants, knowing that Consultant is relying thereon, that:

		a)	The Client is duly organized, validly existing and in good standing
under the laws of the state of Delaware. The Client is qualified to do business as a foreign corporation in each state in which
its business requires it to be so qualified.

 

8) Consultant
Representations. Consultant hereby represents, knowing that the Client is relying thereon, that:

		a)	Consultant has read and accepted the VG LIFE SCIENCES INC. Intellectual
Property Agreement, attached hereto as Exhibit A, which is part of this Agreement and the provisions of which shall survive the
expiration or earlier termination of this Agreement in strict accordance with the time periods as described therein.

 

9)
Extension and Renewal. The Term will automatically renew annually unless terminated
by the Client or Consultant as described in Section 11.

 

10) Indemnification.

		a)	The Client hereby indemnifies and defends the Consultant and
each of her executors, heirs, assigns, and representatives, as applicable, (each, an "Indemnitee") against, and holds
each Indemnitee harmless from, any loss, liability, obligation, deficiency, damage or expense including, without limitation, interest,
penalties, reasonable attorneys' fees and disbursements (collectively, "Damages"), that any Indemnitee may suffer or
incur based upon, arising out of, relating to or in connection with (whether or not in connection with any third party claim):

		i)	any breach of any representation or warranty made by the Client
contained in this Agreement;

		ii)	the failure of the Client to perform or to comply with any covenant
or condition required to be performed or complied with in accordance with this Agreement; and

		iii)	the good faith performance of the Services.

		b)	Indemnification Procedures for Third Party Claims.

		i)	Promptly after notice to an Indemnitee of any claim or the commencement
of any action or proceeding, including any actions or proceedings by a third party (hereafter referred to as "Proceeding"
or "Proceedings"), involving any Damage referred to in this Section, such Indemnitee shall, if a claim for indemnification
in respect thereof is to be made against an Indemnitee pursuant to this Section, give written notice to the Client, setting forth
in reasonable detail the nature thereof and the basis upon which such party seeks indemnification hereunder; provided, however,
that the failure of any Indemnitee to give such notice shall not relieve the Client of its obligations hereunder, except to the
extent that the Client is actually prejudiced by the failure to give such notice.

    	2

     

    

 

		ii)	In the case of any Proceeding by a third party against an Indemnitee,
the Client shall, upon notice as provided above, assume the defense thereof, with counsel reasonably satisfactory to the Indemnitee,
and, after notice from the Client to the Indemnitee of its assumption of the defense thereof, the Client shall not be liable to
such Indemnitee for any legal or other expenses subsequently incurred by the Indemnitee in connection with the defense thereof
(but the Indemnitee shall have the right, but not the obligation, to participate at its own cost and expense in such defense by
counsel of its own choice) or for any amounts paid or foregone by the Indemnitee as a result of any settlement or compromise thereof
that is effected by the Indemnitee (without the written consent of the Client).

		iii)	Anything in this Section 10 notwithstanding, if both the Client
and the Indemnitee are named as parties or subject to such Proceeding and either party determines with advice of counsel that there
may be one or more legal defenses available to it that are different from or additional to those available to the other party or
that a material conflict of interest between such parties may exist in respect of such Proceeding, then the Client may decline
to assume the defense on behalf of the Indemnitee or the Indemnitee may retain the defense on its own behalf, and, in either such
case, after notice to such effect is duly given hereunder to the other party, the Client shall be relieved of its obligation to
assume the defense on behalf of the Indemnitee, but shall be required to pay any legal or other expenses including, without limitation,
reasonable attorneys' fees and disbursements, incurred by the Indemnitee in such defense.

		iv)	If the Client assumes the defense of any such Proceeding, the
Indemnitee shall cooperate fully with the Client and shall appear and give testimony, produce documents and other tangible evidence,
and otherwise assist the Client in conducting such defense. The Client shall not, without the consent of the Indemnitee, consent
to entry of any judgment or enter into any settlement or compromise which does not include as an unconditional term thereof the
giving by the claimant or plaintiff to such Indemnitee of a release from all liability in respect of such claim or Proceeding.
Provided that proper notice is duly given, if the Client shall fail promptly and diligently to assume the defense thereof, then
the Indemnitee may respond to, contest and defend against such Proceeding and may make in good faith any compromise or settlement
with respect thereto, and recover from the Client the entire cost and expense thereof including, without limitation, reasonable
attorneys' fees and disbursements and all amounts paid or foregone as a result of such Proceeding, or the settlement or compromise
thereof. The indemnification required hereunder shall be made by periodic payments of the amount thereof during the course of the
investigation or defense, as and when bills or invoices are received or loss, liability, obligation, damage or expense is actually
suffered or incurred.

 

		c)	The provisions of this Section 10 shall survive the expiration
or earlier termination of this Agreement.

 

11. Termination. Either party may terminate this agreement
at any time during the term hereof with 90 days advance notice by providing written communication to the other party.

 

12. Termination Payment. Upon termination Consultant shall
be entitled to receive only that compensation due and payable hereunder with respect to periods ended on or before the date of
termination, pro-rated if necessary.

    	3

     

    

 

13) Cooperation.
The parties shall deal with each other in good faith, good faith meaning honesty in fact and the observance of all commercial standards
of fair dealing and usages of trade, which are regularly observed within the industry. 

 

14) No
Strict Construction. The language used in this Agreement shall be deemed to be the language chosen by the parties hereto to
express their mutual intent, and no rule of strict construction shall be applied against any party.

 

15)
Arbitration. Any controversy or claim arising out of or relating to this contract, or the breach thereof, shall be settled
by arbitration administered by the American Arbitration Association in accordance with its Commercial Arbitration Rules. If the
parties agree, there shall be one arbitrator; otherwise there shall be a panel of three arbitrators. The cost of
arbitration shall be borne by the Client. Judgment upon the reward rendered may be entered in any court having jurisdiction thereof.

 

16) Governing
Law and Disputes. This Agreement shall be governed by the laws of the State of California, without regard to choice of law
provisions. 

 

17) Waiver.
Any party hereto may waive compliance by the other with any of the terms, provisions and conditions set forth herein; provided,
however, that any such waiver shall be in writing specifically setting forth those provisions waived thereby. No such waiver shall
be deemed to constitute or imply waiver of any other term, provision or condition of this Agreement.

 

18) Severability.
If and to the extent that any court of competent jurisdiction holds any provision or any part thereof of this Agreement to be invalid
or unenforceable, such holding shall in no way affect the validity of the remainder of this Agreement.

 

19) Counterpart
and Headings. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all
of which together shall constitute one and the same instrument. All headings in this Agreement are inserted for convenience of
reference and shall not affect its meaning or interpretation.

 

20) Entire
Agreement. This Agreement is and shall be considered to be the only agreement or understanding between the parties hereto with
respect to the engagement of Consultant by the Client. All negotiations, commitments, and understandings acceptable to both parties
have been incorporated herein. No letter, telegram, or communication passing between the parties hereto shall be deemed a part
of this Agreement; nor shall it have the effect of modifying or adding to this Agreement unless it is distinctly stated in such
letter, telegram, or communication that it is to constitute a part of this Agreement and is to be attached as a rider to this Agreement
and is signed by the parties to this Agreement.

 

21) Modification
of Contract. This Agreement cannot be modified by tender, acceptance or endorsement of any instrument of payment, including
check. Any words contained in an instrument of payment modifying this contract, including a waiver or release of any claims, or
a statement referring to paying in full is void. This Agreement can only be modified in a separate writing, other than an instrument
of payment, signed by the parties.

 

22) Enforcement.
Consultant acknowledges that any remedy at law for
breach of Exhibit A would be inadequate, acknowledges that the Client would be irreparably damaged by an actual or threatened breach
thereof, and agrees that the Client shall be entitled to an injunction restraining Consultant from any actual or threatened breach
of Exhibit A as well as any further appropriate equitable relief without any bond or other security being required. The Client
may pursue enforcement of Exhibit A by commencing an action at law or in equity without first pursuing arbitration pursuant to
Section 16 of this Agreement. In addition to the foregoing, each of the parties hereto shall be entitled to any
remedies available in equity or by statute with respect to the breach of the terms of this Agreement by the other party.

    	4

     

    

 

23) Assignment.
The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto, and their respective heirs,
legal representatives, successors and assigns.

 

24) Notices.
All notices under this Agreement shall be in writing and shall be sent by certified or registered first class mail, return receipt
requested, or shall be personally delivered, or sent by an overnight delivery service such as Federal Express, or shall be transmitted
by telefax (provided such telefax message is confirmed by telephonic acknowledgment of receipt or by sending via other authorized
means a confirmation copy of such notice) addressed to the parties at their respective last known business addresses.

 

Agreed to effective the 10th day
of August, 2015.

 

	VG LIFE SCIENCES INC.	 
	 	 
	/s/ John P. Tynan	/s/ Sanjib Mukherjee
	By: John P. Tynan	By: Sanjib Mukherjee
	 	 
	Its: President and CEO	Its: Consultant

 

    	5

     

    

EXHIBIT A

 

VG LIFE SCIENCES INC. Intellectual Property
Agreement

 

(the “VG LIFE SCIENCES INC. IP Agreement”)

 

In consideration of Consultant entering into that certain Consulting
Agreement dated as of the date hereof (the “Consulting Agreement”) with VG LIFE SCIENCES INC. (“VG”), Consultant
agrees as follows. Capitalized terms used herein that are not defined in this VG LIFE SCIENCES INC. IP Agreement shall be defined
as in the Consulting Agreement.

 

1. Non-Solicitation. Consultant acknowledges that, in the
course of performing Services (as used throughout this VG LIFE SCIENCES, INC. IP Agreement as defined in the Consulting Agreement)
for or on behalf of VG, having access to VG’s technology, reports, processes, materials, knowledge and know-how, data, facilities,
books and records, Consultant may from time to time receive Confidential Information (as defined in Paragraph 2, below) of or with
respect to VG and hereby stipulates and agrees that such Confidential Information is a part of and essential to the operations
and goodwill of VG. In connection and in furtherance of the foregoing, Consultant may not (whether directly or indirectly; as the
principal or on such person’s own account; or solely or jointly with others as an Consultant, agent, independent contractor,
consultant, general or limited partner, member, stockholder or holder of equity securities of any other person, other than through
ownership of less than one percent of a class of publicly-traded securities of a company) engage in any of the conduct or activity
described below in this Paragraph 1.

 

(a)Consultant may not, so long as Consultant is a
Consultant of VG pursuant to the Consulting Agreement and until the third anniversary of the effective date of termination of the
Consulting Agreement for any reason, solicit, induce or influence any person that at such time is (or, during the six (6) month
period ending on the effective date of termination of the Consulting Agreement, was) a vendor, licensor, licensee, distributor,
customer, company, Consultant, or independent contractor of VG, excluding the University, to terminate any contract or agreement
with VG or leave the service of VG. Consultant acknowledges that the restrictions in this subparagraph (a) of this Paragraph 1
will not impair Consultant’s ability to carry on Consultant’s profession or earn a living.

 

(b)Consultant may not, so long as Consultant is a Consultant
of VG and until the third anniversary of the effective date of termination of the Consulting Agreement for any reason, without
the express prior written consent of VG, participate either directly or indirectly in any discussion or negotiation with any person
that at such time is (or, during the six month period ending on the effective date of termination of the Consulting Agreement,
was) a vendor, licensor, licensee, distributor, customer, company, Consultant, or independent contractor of VG the purpose of which
discussion or negotiation would be materially adverse to the interests of VG and the relationship existing between VG and such
person. Consultant acknowledges that the restrictions in this subparagraph (b) of Paragraph 1 will not impair Consultant’s
ability to carry on Consultant’s profession or earn a living.

 

2. Non-Disclosure of Information. Consultant understands
that the covenants and agreements in this Paragraph 2 may limit Consultant’s ability to earn a livelihood in a business similar
to the business of VG of researching, developing and distributing biomedical products and technology, but nevertheless believes
that Consultant has received and will receive sufficient consideration and other benefits from VG so as to clearly justify such
restrictions which, in any event (given Consultant’s education, skills and ability), Consultant does not believe would prevent
Consultant from earning a living:

 

(a)Consultant acknowledges that, in the course of performing
Services for or on behalf of VG, having access to VG’s technology, reports, processes, knowledge and know-how, data, facilities,
books and records, or otherwise being associated with VG, Consultant will have access to, and become acquainted with, Confidential
Information of or with respect to VG and hereby stipulates and agrees that such Confidential Information is a part of and essential
to the operations and goodwill of VG. Consultant (i) hereby stipulates and acknowledges that the Confidential Information constitutes
important, material, proprietary and confidential trade secrets of VG that affect the successful conduct of the business and goodwill
of, VG; (ii) stipulates and acknowledges that any and all of the Confidential Information is the sole and exclusive property of
VG, regardless of whether Consultant was engaged in the development of any of such Confidential Information while performing Services
for or on behalf of VG; (iii) agrees to keep all such Confidential Information in strictest confidence, and not to, directly or
indirectly, use or divulge, disclose or communicate to any person (other than a duly-authorized representative of VG) any such
Confidential Information other than in the ordinary course of business of VG for the benefit of VG; and (iv) agrees not to copy
or otherwise duplicate any such Confidential Information or knowingly allow anyone else to copy or otherwise duplicate such Confidential
Information, other than in the ordinary course of business of VG for the benefit of VG. Upon the termination of the Consulting
Agreement, and at any time at the request of VG, shall promptly return to VG all copies of such Confidential Information delivered
to or obtained by Consultant or, at the election of VG, certify that all copies of such Confidential Information in the possession
of Consultant or any person who received such Confidential Information from Consultant have been destroyed or erased, except that
Consultant may keep one (1) copy thereof for the purpose of complying with the terms of this Agreement.

    	6

     

    

 

 

(b)“Confidential Information” means,
with respect to VG, any technical, financial, or business information (including, without limitation, manuals, forms, memoranda,
reports, journals, data, test results, correspondence, business plans, customer lists, pricing lists, contracts, plans or specifications,
or the like) that may disclose (or may reasonably be expected to disclose) the customs and practices, marketing methods and data,
services and products, methods of doing business, manner of operation, know-how, formulas, technical data or information, clinical
study protocols, patient or biologic information, manufacturing information or know-how, methods, processes, compounds, and other
confidential information, regardless of whether in written, oral, graphic, encoded, encrypted, tangible, or intangible forms, all
of which the Consultant hereby acknowledges constitute “trade secrets” within the meaning of the Uniform Trade Secrets
Act, codified at Sections 3426 et seq. of the California Civil Code.

 

(c)Consultant shall have no obligation to preserve the confidential
or proprietary nature of any information that (i) was already known to Consultant free of any obligation to keep such information
confidential at the time of disclosure of such information; (ii) is or becomes publicly known through no wrongful act of Consultant;
(iii) is rightfully received from a third person having no direct or indirect secrecy or confidentiality obligation to VG; (iv)
is disclosed to a third person by VG without restrictions on confidentiality similar to those contained in this Paragraph 2; (v)
is approved for disclosure by written authorization of VG; (vi) is developed by Consultant or on Consultant’s behalf independently
of the information disclosed to Consultant by VG as shown by written record; or (vii) Consultant is obligated to produce pursuant
to an order of a court of competent jurisdiction or a valid administrative or Congressional subpoena, provided that Consultant
promptly notifies VG and cooperates reasonably with VG’s efforts to contest or limit the scope of such order.

 

(d)Except for the assignment provisions as provided in Section
3 of this VG LIFE SCIENCES INC. IP Agreement, the provisions of this Paragraph 2 shall apply to Consultant throughout the
term of the Consulting Agreement and continue in perpetuity.

 

3. Assignment of Inventions. Consultant shall promptly disclose
any Consultant Creations (as defined below) to VG and any such Consultant Creations shall be VG’s sole property. All original
works of authorship that are made by Consultant (in whole or in part, either alone or jointly with others) during and in the performance
of the Services and that are protectable by copyright are “works made for hire” as defined in the United States Copyright
Act (17 U.S.C.A. Section 101). “Consultant Creation(s)” means any idea, concept, discovery, development, device, design,
apparatus, use, machine, practice, process, method, product, composition of matter, improvement, formula, algorithm, literary or
graphical or audiovisual work or sound recording, mask work, or computer program of any kind (whether or not subject to patent,
copyright, trademark, trade secret, mask work right, or similar protection) that relate(s) in any way to any of VG’s biological
or pharmaceutical products under investigation or development from time to time, or any manufacturing or production know-how, scientific
know-how, processes, or procedures pertaining thereto that are made by Consultant, in whole or in part, either solely or jointly
with others, during and in the performance of the Services, provided, however, that Consultant does not have a pre-existing obligation
to assign any such Consultant Creation to the University. Consultant shall promptly notify VG in advance or at the earliest reasonable
time if any work being performed or proposed by VG to be performed by Consultant under this Agreement may give rise to Consultant
Creations that may be assignable to University under any agreements.

 

(a)Consultant hereby assigns to VG, and agrees to assign
to VG in the future where appropriate, any and all such Consultant Creations, and agrees to cooperate with VG in the execution
of appropriate instruments assigning and evidencing such assignment and ownership rights of VG, to the maximum extent permitted
by Section 2870 of the California Labor Code. In order that VG may perfect and protect its rights to Consultant Creations as provided
hereunder, Consultant agrees that Consultant’s obligations regarding assignment of such Consultant Creations to VG shall
survive termination of Consultant’s engagement with VG for a term of three years following the date of termination of the
Consulting Agreement for any reason.

 

4. Enforcement. Consultant acknowledges that the covenants
and the restrictions contained in this Agreement are necessary and required for the adequate protection of VG and are necessary
to preserve the goodwill of VG and the value of its existing Confidential Information, inventions, contracts and relationships;
such covenants relate to matters that are of a special, unique and extraordinary character that give each of such covenants or
restrictions a special, unique and extraordinary value; and, a breach of any such covenant or restriction will result in loss of
goodwill, invasion of property rights of VG, unfair competition by the breaching party, and other irreparable harm and damages
to VG, which cannot be adequately compensated by a monetary award. It
is accordingly agreed that VG or any of its subsidiaries shall be entitled to an injunction or injunctions to prevent breaches
of this Agreement and to enforce specifically the terms and provisions of this Agreement. Nothing in this Agreement
shall be construed as prohibiting VG from pursuing any other legal or equitable remedies available to VG for such breach or threatened
breach of any of the provisions of this Agreement (including, without limitation, recovery of all damages from Consultant and an
equitable accounting of all earnings, profits and other benefits arising from such violation).

    	7

     

    

 

 

5. Conflict. In the event of any conflict between any provision
in this Agreement and any provision in the Consulting Agreement, the provision(s) in the Consulting Agreement shall govern.

 

	
        AGREED:

         

        CONSULTANT

         

         

        /s/ Sanjib Mukherjee

         

         

         

        VG LIFE SCIENCES INC.

         

        /s/ John P. Tynan

        Its: President and CEO

         
	
         

         

         

         

         

        DATED: August 10, 2015

         

         

         

         

         

        DATED: August 10, 2015

         

 

 

 

 

 

 

    	8Exhibit 10.179

 

CONVERTIBLE PROMISSORY
NOTE AND WARRANT PURCHASE AGREEMENT

 

THIS CONVERTIBLE PROMISSORY
NOTE AND WARRANT PURCHASE AGREEMENT is made as of May 14, 2015, by and among Hock Tiam Tay (the “Investor”) and VG
Life Sciences Inc. (the "Company" or “VGLS”).

 

THE PARTIES HEREBY AGREE
AS FOLLOWS:

 

1.          Purchase and Sale of Notes.

 

1.1          Purchase and Sale
of Note. Subject to the terms and conditions of this Agreement and pursuant to promissory notes in the form attached hereto
as Exhibit A (each a "Note" and, collectively, the “Notes), the Investor agrees to purchase at the Closing and
the Company agrees to sell and issue to the Investor at the Closing and thereafter Notes in the principal amount of at least Fifty
Thousand Dollars ($50,000) and up to a maximum of One Hundred Thousand Dollars ($100,000) at an amount equal to the face value
of the Note(s) (the "Investment"). Investor will purchase an initial Note in the minimum amount of Fifty Thousand ($50,000)
in cash at the Closing, but shall be entitled to purchase any amount in cash up to an aggregate of $100,000, such additional payments
to be made no later than May 13, 2016. A separate Note will be issued to Investor immediately upon tender of additional amounts
as contemplated herein. The Warrant (as defined in Section 1.2 below) includes a cashless exercise feature enabling conversion
into unregistered shares (“Shares”) of common stock of VGLS based on the spread between the warrant exercise price
and the then- trading value of the underlying VGLS Shares. The Note is convertible into Shares at a conversion rate equal to the
lowest consecutive three-day average closing price of the Shares starting on January 12, 2015 and ending on February 11, 2015 (the
“Period”), minus a ten percent (10%) discount. Investor may not convert for one year after the date of the investment.
Then the Note will be convertible into Shares in four equal tranches (25% each) on the quarter anniversary of the date of a given
note commencing fifteen months and for each of the three succeeding quarters. With respect to the Note: (a) it bears interest at
the rate of eight percent (8%) per annum, (b) any unconverted principal and interest remaining on the Note on May 13, 2017 shall
be automatically converted into Shares on such date, and (c) it will not be prepayable by VGLS. Notwithstanding the foregoing,
the Investor may convert all or any portion of the Notes, solely at the option of the Investor, except that the lock up restrictions
remain in effect. The maturity date for all notes shall be May 13, 2017.

 

1.2          Purchase
and Sale of Warrant. Subject to the terms and conditions of this Agreement, the Investor agrees to purchase and the Company
agrees to sell and issue to the Investor at the Closing, a warrant in the form attached hereto as Exhibit B (the "Warrant")
to purchase shares of the Company's Common Stock. In addition to the Notes, Investor will receive warrant coverage (“Warrants”)
for four Shares for every one dollar ($1.00) of cash provided to the Company under Section 1.1 above, with each Warrant to be
exercisable by Investor at the Price, as stated in Section 1.1 above, multiplied by 7.5, which includes a cashless exercise feature.
The Warrants will be exercisable on any date after the four-year anniversary of the date of this Agreement and expire on the five-year
anniversary of the date of this Agreement.

 

    	1

    	 

    

 

1.3          Closing.

 

(a)          The purchase and
sale of the initial Note and Warrants shall take place upon execution of this Agreement, or at such other time and place as the
Company and the Investor may determine (the "Closing").

 

(b)          At the Closing, the
Company shall deliver to the Investor a Note representing the principal amount as is prescribed in Section 1.1 above and the Investor
shall cause to be delivered to the Company a wire transfer to the Company's order in the aggregate amount of the principal amount
of the Investment as is prescribed in Section 1.1 above.

 

(c)          Following the Closing
the Company shall deliver additional Notes and Warrants as the cash or Services described in Section 1.1 above are provided to
the Company.

 

1.4          Change
of Control. Notwithstanding anything to the contrary set forth in this Agreement, in the event of a “Change of
Control” of VGLS, Investor shall be entitled to receive (prior to the close of any such Change of Control) any
remaining Notes and the Shares to which Investor would have been entitled to under the Notes or the conversion thereof absent
such Change of Control. In addition to the foregoing, in the event of a Change of Control of VGLS, Investor shall be entitled
to receive and exercise (prior to the close of any such Change of Control) any and all corresponding Warrants to which it
would have been entitled under Sections 1.1 and 1.2 above during the full term of this Agreement absent such Change of
Control, and the Shares exercisable under the Warrants. For purposes of this Section 1.4 a “Change in Control”
shall mean; (a) the closing of the sale, transfer or other disposition of all or substantially all of the VGLS’s
assets, (b) the consummation of the merger or consolidation of VGLS with or into another entity (except a merger or
consolidation in which the holders of capital stock of VGLS immediately prior to such merger or consolidation continue to
hold at least fifty percent (50%) of the voting power of the capital stock of VGLS or the surviving or acquiring entity), or
any transaction or series of transactions to which VGLS is a party in which in excess of fifty percent (50%) of VGLS’s
voting power is transferred, or (c) the exclusive license of all or substantially all of the intellectual property of VGLS to
a third party.

 

2.          Representations,
Warranties, and Covenants of the Company. The Company hereby represents and warrants to the Investor that:

 

2.1          Organization,
Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under
the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as now
conducted and proposed to be conducted. The Company is duly qualified to transact business and is in good standing in each
jurisdiction in which the failure to so qualify would have a material adverse effect on its business or properties.

 

    	2

    	 

    

 

2.2          Authorization.
All corporate actions on the part of the Company, its officers, directors and stockholders necessary for the authorization, execution
and delivery of this Agreement, the performance of all obligations of the Company hereunder and the authorization, issuance and
delivery of the Notes and the Warrants have been taken or will be taken prior to the Closing. This Agreement constitutes, and the
Notes and the Warrants when executed and delivered in accordance with their terms will constitute, valid and legally binding obligations
of the Company, enforceable in accordance with their respective terms except (i) as limited by applicable bankruptcy, insolvency,
reorganization, moratorium, and other laws of general application affecting enforcement of creditors' rights generally, (ii) as
limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies and (iii)
as limited by applicable usury laws.

 

2.3          Compliance
with Other Instruments. The Company is not in violation or default of any provisions of its Articles of Incorporation,
as amended (the "Articles"), or Bylaws (the "Bylaws"), or, except as set forth on Schedule 1 hereof, in
any material respect of any provision of a mortgage, indenture, agreement, instrument or contract to which it is a party or
by which it is bound or of any federal or state judgment order, writ or decree, or, to its knowledge, of any statute, rule or
regulation applicable to the Company. The execution, delivery and performance by the Company of this Agreement, and the
consummation of the transactions contemplated hereby, including the issuance and delivery of the Notes and the Warrants, will
not result in any such violation or be in material conflict with or constitute, with or without the passage of time or giving
of notice, either a material default under any such provision or an event that results in the creation of any material lien,
charge or encumbrance upon any assets of the Company or the suspension, revocation, impairment, forfeiture, or nonrenewal of
any material permit, license, authorization, or approval applicable to the Company, its business or operations, or any of its
assets or properties.

 

2.4          Governmental Consents.
Based in part upon the representations and warranties of the Investor in Section 3, no consent, approval, order or authorization
of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority
on the part of the, Company is required in connection with the consummation of the transactions contemplated by this Agreement,
except such post-closing filings as may be required under applicable federal and state securities laws, which will be timely filed
within the applicable period therefor.

 

2.5          Sufficient
Authorized Shares. The number of authorized but unissued shares of the Company's Common Stock will be sufficient to
permit conversion of the Notes and the exercise of the Warrants. From the date hereof, the Company shall at all times
maintain a sufficient quantity of authorized but unissued shares of Common Stock sufficient to permit conversion of the Notes
and the exercise of the Warrants. In the event the Company, for any reason, no longer has a sufficient number of authorized
but unissued shares to comply with this Section 2.5, it shall use its best efforts to promptly authorize such shares. Upon
the issuance of shares of Common Stock pursuant to the conversion of the Notes and/or the exercise of the Warrants, such
shares of Common Stock shall be duly and validly issued, fully paid and nonassessable, and issued in compliance with all
applicable securities laws, as then in effect, of the United States and each of the states whose securities laws govern the
issuance of the Notes and/or the Warrants pursuant to this Agreement and shall not be issued in violation of any preemptive
or similar right.

 

    	3

    	 

    

 

2.6          No Brokers.
No broker or finder has acted directly or indirectly for the Company in connection with the transactions contemplated by this
Agreement, and no broker or finder is entitled to any brokerage, finder's or other fee or commission in respect thereof based
in any way on agreements, arrangements or understandings made by or on behalf of the Company and the Investor or the transactions
contemplated hereby.

 

2.7          Minute
Books. The Company has made available to the Investor (and will continue to make available up to the Closing) copies of
the minute books of the Company. The minute books contains records of all written actions and meetings of the Board of
Directors and there have been no written actions or meetings of the Board of Directors

since the date of the last
meeting in the minute books.

 

3.          Representations and
Warranties of the Investor. The Investor represents and warrants severally and not jointly, with respect to the Investor, that:

 

3.1          Authorization. The
Investor has full capacity, power and authority to enter into and perform this Agreement, and all actions necessary to authorize
the execution, delivery and performance of this Agreement have been taken prior to the Closing. This Agreement constitutes a valid
and legally binding obligation of the Investor, enforceable in accordance with its terms, except as the same may be limited by
bankruptcy, insolvency, moratorium, and other laws of general application affecting the enforcement of creditors' rights generally.

 

3.2          Receipt
of Information. The Investor believes it, he or she has received all the information necessary or appropriate for
deciding whether to acquire the Securities. The Investor further represents that the Investor has had an opportunity to ask
questions and receive answers from the Company regarding the terms and conditions of the offering of the Securities.

 

3.3          Investment Experience.
The Investor is an investor in securities of companies in the development stage and acknowledges that the Investor is able to fend
for itself, herself or himself, can bear the economic risk of its, his or her investment and has such knowledge and experience
in financial or business matters that the Investor is capable of evaluating the merits and risks of the investment in the Securities.
If other than an individual, the Investor also represents it has not been organized for the purpose of acquiring the Securities.
The Investor further represents that the information provided on Investor's counterpart signature page is true and accurate.

 

3.4          Restricted
Securities. The Investor understands that the Securities are characterized as "restricted securities" under
the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public
offering and that under such laws and applicable regulations such securities may be resold without registration under the
Securities Act of 1933, as amended (the "Securities Act") only in certain limited circumstances. In connection
therewith, each lender represents that it is familiar with Rule 144 under the Securities Act, as presently in effect, and
understands the resale limitations imposed thereby and by the Securities Act.

 

    	4

    	 

    

 

3.5          Legends. To the extent
applicable, each certificate or other document evidencing any of the Securities shall be endorsed with the legend set forth below,
and the Investor covenants that, except to the extent such restrictions are waived by the Company, the Investor shall not transfer
the Securities represented by any such certificate without

complying with the restrictions on transfer described
in the legends endorsed on such certificate:

 

"THE SECURITIES REPRESENTED
HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED,
PLEDGED, OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH RULE 144 PROMULGATED
UNDER SUCH ACT, OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT
SUCH REGISTRATION IS NOT REQUIRED."

 

4.          Conditions of
Investor's Obligations. The obligations of the Investor hereunder are subject to the fulfillment on or before the Closing
of each of the following conditions:

 

4.1          Representations and Warranties.
The representations and warranties of the Company contained in Section 2 shall be true on and as of the Closing with the same effect
as though such representations and warranties had been made on and as of the date of such Closing.

 

4.2          Performance.
The Company shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that
are required to be performed or complied with by it on or before the Closing.

 

4.3          Board Actions.
The Company shall have delivered to the Investor resolutions duly adopted by the Company's Board of Directors and, to the extent
required by applicable law or by the Company's Articles of Incorporation, the Company's Shareholders, and certified by the Secretary
of the Company (i) approving and authorizing the Company's execution and delivery of this Agreement, the Notes and the Warrants,
and the Company's performance thereunder, and (ii) authorizing the reservation of a sufficient number of shares of the Company's
Common Stock to permit the conversion of the Notes and to permit the exercise of the Warrants.

 

5.          Conditions
of the Company's Obligations. The obligations of the Company with respect to the Investor under this Agreement are subject
to the fulfillment on or before the Closing of each of the following conditions:

 

5.1          Representations and Warranties.
The representations and warranties of the Investor contained in Section 3 and on the Investor's signature page shall be true on
and as of the Closing with the same effect as though such representations and warranties had been made on and as of the Closing.

 

    	5

    	 

    

 

5.2          Delivery of Principal.
The Investor shall have delivered the principal amount of the Investor's Investment as is prescribed in Section 1.1.

 

6.          Post-Closing
Covenant of Company. During such times as any Note is outstanding, the Company shall provide the Investor with a weekly update
of the Company's actual and forecasted cash position and of any reasonably significant development related to the Company or its
business. Such weekly updates shall be transmitted to the Investor via facsimile or via e-mail, at a facsimile number or e-mail
address provided by the Investor, no later than noon pacific time each Monday during which such obligation remains in effect.

 

7.          Events
of Default.

 

Upon the occurrence of any
of the following specified events (each an "Event of Default"), unless such Event of Default shall have been waived or
cured prior to the exercise of the remedies set forth below:

 

7.1          Payments.
Any default by the Company in the payment when due of any principal and unpaid accrued interest under any Note if such default
is not cured by the Company within ten (10) days after the holder of such Note has given the Company written notice of such default;

 

7.2          Representations
and Warranties. Any representation or warranty made by the Company herein shall prove to have been incorrect in any material
respect on or as of the date made and remains unremedied for a period of thirty (30) days after any Investor provides the Company
with written notice of such breach;

 

7.3          Post Closing Covenants.
The failure of Company to satisfy any of the post-closing covenants set forth in Section 6 hereof within the time-periods set
forth therein.

 

7.4          Institution
of Bankruptcy Proceedings. The institution by the Company of proceedings to be adjudicated as bankrupt or insolvent, or
the consent by it to institution of bankruptcy or insolvency proceedings against it or the filing by it of a petition or
answer or consent seeking reorganization or release under the federal Bankruptcy Act, or any other applicable federal or
state law, or the consent by it to the filing of any such petition or the appointment of a receiver, liquidator, assignee,
trustee, or other similar official, of the Company, or of any substantial part of its property, or the making by it of an
assignment for the benefit of creditors, or the taking of corporate action by the Company in furtherance of any such action;
or

 

    	6

    	 

    

 

7.5          Continuation of Bankruptcy
Proceedings. If, within thirty (30) days after the commencement of an action against the Company (and service of process in
connection therewith on the Company) seeking any bankruptcy, insolvency, reorganization, liquidation, dissolution or similar relief
under any present or future statute, law or regulation, such action shall not have been resolved in favor of the Company or all
orders or proceedings thereunder affecting the operations or the business of the Company stayed, or if the stay of any such order
or proceeding shall thereafter be set aside, or if, within thirty (30) days after the appointment without the consent or acquiescence
of the Company of any trustee, receiver or liquidator of the Company or of all or any substantial part of the properties of the
Company, such appointment shall not have been vacated;

 

Then, and in any such event, and at
any time thereafter, if any events shall be continuing, the Investor shall have the option to declare the principal amount of
the Notes, and all accrued but unpaid interest thereon, to be immediately due and payable upon written notice to the
Company.

 

8.          Miscellaneous.

 

8.1          Successors and Assigns.
No party may assign any of its rights or delegate any of its obligations under this Agreement without the prior written consent
of the other party. Any purported assignment of rights or delegation of obligations in violation of this Section 8.1 shall be void.
This Agreement will apply to and be binding in all respects upon, and inure to the benefit of heirs, executors, administrators,
legal representatives, and permitted assigns of the parties.

 

8.2          Governing Law.
This Agreement shall be governed by and construed under the laws of the State of California, without giving effect to principles
of conflict of laws.

 

8.3          Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.

 

8.4          Titles and Subtitles.
The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting
this Agreement.

 

8.5          Notices. Unless
otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively
given upon personal delivery to the party to be notified or four (4) days after deposit with the United States Post Office, by
registered or certified mail, postage prepaid and addressed to the party to be notified at the address indicated for such party
on the signature page hereof, or at such other address as such party may designate by advance written notice to the other parties.

 

    	7

    	 

    

 

8.6          Finder's Fee.
Each party represents that it neither is nor will be obligated for any finders' fee or commission in connection with this transaction.

 

8.7          Entire Agreement.
This Agreement and the other documents delivered pursuant hereto constitute the entire agreement among the parties and no party
shall be liable or bound to any other party in any manner by any warranties, representations, or covenants except as specifically
set forth herein or therein.

 

8.8          Amendment
and Waiver. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either
generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company and
the Investor. This provision shall not affect the amendment and waiver provisions of the Note. Any waiver or amendment effected
in accordance with this section shall be binding upon each holder of any Securities purchased under this Agreement at the time
outstanding, each future holder of all such Securities, and the Company.

 

8.9          Severability.
If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be
excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and
shall be enforceable in accordance with its terms.

 

8.10          Survival. The representations,
warranties, covenants and agreements made herein shall survive the Closing for a period of 12 months.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

    	8

    	 

    

 

IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first above written.

 

 

 

 

VG Life Sciences, Inc.

 

 

 

 

/s/ John P. Tynan

By: John P. Tynan

Title: President & CEO

 

 

 

 

Hock Tiam Tay

 

 

 

 

/s/ Hock Tiam Tay

By: Hock Tiam Tay

 

    	9

    	 

    

 

EXHIBIT A

 

VG LIFE SCIENCES,
INC. CONVERTIBLE PROMISSORY NOTE

 

 

THIS
CONVERTIBLE PROMISSORY NOTE (“Note”) is issued as of May 14, 2015 (the “Original Issue Date”), by VG Life
Sciences, Inc., a Delaware corporation (the “Company”), in an aggregate principal amount of $50,000.00.

 

Terms not otherwise defined herein shall have the meanings
given in Section 6 below.

 

FOR VALUE
RECEIVED, the Company promises to pay to Hock Tiam Tay, or registered assigns (the “Holder”), the principal sum of
Fifty Thousand Dollars ($50,000.00), on or before May 13, 2017 (the “Maturity Date”) and to pay interest to the Holder
on the principal sum, at the rate per annum of eight percent (8%). Interest shall accrue daily commencing on the Original Issue
Date until payment in full of the principal sum, together with all accrued and unpaid interest, has been made or duly provided
for. Interest shall be calculated on the basis of a 360-day year. Interest hereunder will be due and payable at the Maturity Date,
to the person in whose name this Note is registered on the records of the Company (the “Note Register”). The principal
of, and interest on, this Note are payable in such coin or currency of the United States of America as at the time of payment is
legal tender for payment of public and private debts, at the address of the Holder last appearing on the Note Register. A transfer
of the right to receive principal and interest under this Note shall be transferable only through an appropriate entry in the Note
Register as provided herein.

 

This Note is subject to the following additional provisions:

 

Section
1.          Convertible Note and Warrant Purchase Agreement. This
Note is one of the Notes issued pursuant to that certain Convertible Note and Warrant Purchase Agreement (the “Agreement”)
between the Company and Holder dated as of May 14, 2015. This Note is subject to, and qualified by, all the terms and conditions
set forth in the Agreement.

 

Section 2.          Events of Default.

 

Section
2.1          Events of Default Defined; Acceleration of Maturity.
If an Event of Default (as defined in the Agreement) has occurred then upon the occurrence of any such Event of Default, the Holder
may, by notice to the Company, declare the unpaid principal amount of the Notes to be, and the same shall forthwith become, due
and payable, without presentment, demand, protest or other notice of any kind, all of which are hereby waived by the Company,
together with the interest accrued thereon and all other amounts payable by the Company hereunder and pursue all of Holder’s
rights and remedies hereunder and under the other Loan Documents and all other remedies available to Holder under applicable law.

 

    	10

    	 

    

 

Section
3.          Optional Conversion.

 

(a)          The
outstanding principal and all accrued and unpaid interest of this Note shall be convertible, at the option of the Holder, into
shares of common stock of the Company (“Common Stock”) at the Conversion Ratio, in four equal tranches (25% each) on
the following dates: August 14, 2016, November 14, 2016, February 14, 2017, and May 13, 2017. Any conversion under this Section
3(a) shall be of a minimum amount of US $5,000 of Notes. The Holder shall effect conversions by surrendering the Notes (or
such portions thereof) to be converted to the Company, together with the form of conversion notice attached hereto as Exhibit
A (the “Conversion Notice”) in the manner set forth in Section 3(h). Each Conversion Notice shall specify
the principal amount of Notes to be converted and the date on which such conversion is to be effected (the “Conversion Date”).
Subject to Section 3(b), each Conversion Notice, once given, shall be irrevocable. If the Holder is converting less than
all of the principal amount represented by the Note(s) tendered by the Holder with the Conversion Notice, the Company shall promptly
deliver to the Holder a new Note for such principal amount as has not been converted.

 

(b)          Not later
than fifteen (10) Business Days after the Conversion Date, the Company will deliver to the Holder (i) a certificate or certificates
containing the restrictive legends and trading restrictions required by law, if any, representing the number of shares of Common
Stock being acquired upon the conversion of Notes and (ii) Notes in principal amount equal to the principal amount of Notes not
converted; provided, however that the Company shall not be obligated to issue certificates evidencing the shares of Common
Stock issuable upon conversion of any Notes, until Notes are either delivered for conversion to the Company or any transfer Holder
for the Notes or Common Stock, or the Holder notifies the Company that such Notes have been lost, stolen or destroyed and provides
a lost instrument indemnity to the Company to indemnify the Company from any loss incurred by it in connection therewith. If such
certificate or certificates are not delivered by the date required under this Section 3(b), the Holder shall be entitled
by written notice to the Company at any time on or before its receipt of such certificate or certificates thereafter, to rescind
such conversion, in which event the Company shall immediately return the Notes tendered for conversion.

 

(c)          (i)          The conversion
price (“Conversion Price”) for each Note in effect on any Conversion Date shall be 10% less than the lowest 3 day average
during the period beginning January 12, 2015 and ending February 11, 2015, subject to adjustment as otherwise contemplated by this
Section 3(c).

 

    	11

    	 

    

 

(ii)          In
case of any Acquisition (as defined below) of the Company, then Holder shall have the right thereafter to convert any principal
and interest remaining owing under this Note prior to the closing of any such Acquisition. At the election of Holder, Holder may
convert this Note into the shares of stock and other securities and property receivable upon or deemed to be held by holders of
Common Stock following such Acquisition, and the Holder shall be entitled upon such event to receive such amount of securities
or property as the shares of the Common Stock, into which the Note could have been converted immediately prior to such Acquisition,
would have been entitled. The terms of any such Acquisition shall include such terms so as to continue to give to the Holder the
right to receive the securities or property set forth in this Section 3(c) upon any conversion following such Acquisition.
This provision shall similarly apply to successive Acquisitions. “Acquisition” means (a) the closing of the sale,
transfer or other disposition of all or substantially all of the VGLS’s assets, (b) the consummation of the merger or consolidation
of VGLS with or into another entity (except a merger or consolidation in which the holders of capital stock of VGLS immediately
prior to such merger or consolidation continue to hold at least fifty percent (50%) of the voting power of the capital stock of
VGLS or the surviving or acquiring entity), or any transaction or series of transactions to which VGLS is a party in which in
excess of fifty percent (50%) of VGLS’s voting power is transferred, or (c) the exclusive license of all or substantially
all of the intellectual property of VGLS to a third party

 

(iii)          The Conversion Price shall be subject to adjustment as follows:

 

(A)          In case
the Company shall (i) pay a dividend in shares of its capital stock, (ii) subdivide its outstanding shares of Common Stock, (iii)
combine its outstanding shares of Common Stock into a smaller number of shares, or (iv) issue by reclassification of its shares
of Common Stock any shares of the Company, the Conversion Price in effect immediately prior thereto shall be adjusted so that the
Holder of this Note thereafter surrendered for conversion shall be entitled to receive the number of shares of Common Stock which
he would have owned or have been entitled to receive after the happening of any of the events described above, had this Note been
converted immediately prior to the happening of such event. Such adjustment shall be made whenever any of the events listed above
shall occur. An adjustment made pursuant to this subdivision (A) shall become effective retroactively immediately after the record
date in the case of a dividend and shall become effective immediately after the effective date in the case of a subdivision, combination
or reclassification.

 

(B)          If,
at any time while this Note is outstanding, the Company takes any voluntary action or any event occurs as to which the foregoing
subdivisions are not strictly applicable, but the failure to make an adjustment in the Conversion Price hereunder would not fairly
protect the rights, without dilution, represented by this Note, then the Conversion Price in effect immediately prior thereto shall
be adjusted so that the Holder of this Note shall be entitled to receive the number of shares of Common Stock which he would have
owned or been entitled to receive after the happening of any such action or event, had this Note been converted immediately prior
to the happening of any such action or event.

 

(d)          The Company
covenants that it will at all times reserve and keep available out of its authorized and unissued Common Stock solely for the purpose
of issuance upon conversion of Notes as herein provided, free from preemptive rights or any other actual contingent purchase rights
of persons other than the holders of Notes, such number of shares of Common Stock as shall be issuable upon the conversion of the
aggregate principal amount of all outstanding Notes. The Company covenants that all shares of Common Stock that shall be so issuable
shall, upon issue, be duly and validly authorized, issued and fully paid and nonassessable.

 

    	12

    	 

    

 

(e)          Upon
a conversion hereunder the Company shall not be required to issue stock certificates representing fractions of shares of
Common Stock, but may, if otherwise permitted, make a cash payment in respect of any final fraction of a share based on the
Conversion Price at such time.

 

(f)          The
issuance of certificates for shares of Common Stock on conversion of Notes shall be made without charge to the Holder for any
documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such certificate, provided that
the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery
of any such certificate upon conversion in a name other than that of the Holder and the Company shall not be required to issue
or deliver such certificates unless or until the person or persons requesting the issuance thereof shall have paid to the Company
the amount of such tax or shall have established to the satisfaction of the Company that such tax has been paid.

 

(g)          Notes converted
into Common Stock shall be canceled.

 

(h)          Each Conversion
Notice shall be given by email or mail, postage prepaid, addressed to the Controller of the Company of VG Life Sciences, Inc. located
121 Gray Avenue, Suite 200, Santa Barbara, CA 93101. Any such notice shall be deemed given and effective upon the earliest to occur
of (i) receipt of such email at the email address specified in this Section 3(h), (ii) five days after deposit in the United
States mails or (iii) upon actual receipt by the party to whom such notice is required to be given.

 

Section 4.          Mandatory Conversion.

 

(a)          In
the event Holder has not elected to convert all of the principal and interest remaining owing under this Note on or prior to two
years after the date of this note, the then outstanding principal and accrued and unpaid interest amount of this Note shall, without
further action by the Holder or the Company, be automatically converted in whole into that number of shares of Common Stock of
the Company at the Conversion Ratio on the Maturity Date (the “Mandatory Conversion Date”).

 

(b)          Not later
than ten (10) Business Days after the Mandatory Conversion Date, the Company will deliver to the Holder a certificate or certificates
containing the restrictive legends and trading restrictions required by law, if any, representing the number of shares of Common
Stock being acquired upon the mandatory conversion of this Note; provided, however that the Company shall not be obligated
to issue certificates evidencing the equity securities issuable upon conversion of this Note, until the Note is either delivered
for conversion to the Company or any transfer Holder of the Note or Common Stock, or the Holder notifies the Company that the Note
have been lost, stolen or destroyed and provides a lost instrument indemnity or bond to the Company to indemnify the Company from
any loss incurred by it in connection therewith. The Company covenants and agrees that it shall comply with Sections 3(d)
through (g) with respect to any mandatory conversion and such sections are incorporated by reference herein.

 

    	13

    	 

    

 

Section 5.          Payment of Principal and Redemption.

 

(a)          In
the event of an occurrence of an Event of Default, then the outstanding principal balance of this Note shall be due and payable
in full on the Maturity Date. Prior to the Mandatory Conversion Date this Note may not be prepaid.

 

(b)          Nothing
in this Section 5 shall impair the Holder’s right to convert this Note pursuant to Section 3 prior to the Mandatory Conversion
Date.

 

Section
6.          Definitions. For the purposes hereof, the following terms
shall have the following meanings:

 

“Business Day” shall mean
any day, except a Saturday, Sunday or other day on which commercial banks in the State of California are authorized or
required by law to close.

 

“Conversion
Ratio” means, at any time, a fraction, of which the numerator is the outstanding principal amount represented by any Note
plus accrued but unpaid interest, and of which the denominator is the Conversion Price at such time.

 

“Original
Issue Date” means the date of the first issuance of this Note regardless of the number transfers hereof.

 

Section
7.          Stockholder Rights. This Note shall not entitle the Holder
to any of the rights of a stockholder of the Company, including without limitation, the right to vote, to receive dividends and
other distributions, or to receive any notice of, or to attend, meetings of stockholders or any other proceedings of the Company,
unless and to the extent converted into shares of Common Stock in accordance with the terms hereof.

 

Section
8.          Lost Note. If this Note shall be mutilated, lost, stolen
or destroyed, the Company shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated Note,
or in lieu of or in substitution for a lost, stolen or destroyed debenture, a new Note for the principal amount of this Note so
mutilated, lost, stolen or destroyed but only upon receipt of evidence of such loss, theft or destruction of such Note, and of
the ownership hereof, and indemnity or bond, if requested, all reasonably satisfactory to the Company.

 

Section
9.          Governing Law. This Note shall be governed by and construed
in accordance with the laws of the State of California, without giving effect to conflicts of laws thereof.

 

Section
10.          Notices. All notices or other communications hereunder
shall be given, and shall be deemed duly given and received, if given, in the manner set forth in Section 5(h).

 

    	14

    	 

    

 

Section
11.          Waiver. Any waiver by the Company or the Holder a
breach of any provision of this Note shall not operate as or be construed to be a waiver of any other breach of such
provision or of any breach of any other provision of this Note. The failure of the Company or the Holder to insist upon
strict adherence to any term of this Note on one or more occasions shall not be considered a waiver or deprive that party of
the right thereafter to insist upon strict adherence to that term or any other term of this Note. Any waiver must be in
writing.

 

Section
12.          Severability. If any provision of this Note is invalid,
illegal or unenforceable, the balance of this Note shall remain in effect, and if any provision is inapplicable to any person
or circumstance, it shall nevertheless remain applicable to all other persons and circumstances.

 

IN WITNESS WHEREOF, the Company has
caused this instrument to be duly executed by an officer thereunto duly authorized as of the date first above indicated.

 

VG LIFE SCIENCES, INC.,

a Delaware corporation

 

 

By:________________________

Name: John P. Tynan

Title: President & CEO

 

    	15

    	 

    

 

EXHIBIT A

 

NOTICE OF CONVERSION

AT THE ELECTION OF HOLDER

 

(To be Executed by the Registered Holder in order
to Convert the Note)

 

The undersigned hereby irrevocably
elects to convert the above Note into shares of Common Stock, no par value per share (the “Common Stock”), of VG Life
Sciences, Inc. (the “Company”) according to the conditions hereof, as of the date written below. If shares are to be
issued in the name of a person other than undersigned, the undersigned will pay all transfer taxes payable with respect thereto
and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee
will be charged to the Holder for any conversion, except for such transfer taxes, if any.

 

 

 

 

	Conversion calculations:	
	 	Date to Effect Conversion
	 	 
	 	 
	 	Principal
Amount of Notes to be Converted
	 	 
	 	 
	 	Applicable
Conversion Price
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name:

  

    	16

    	 

    

 

EXHIBIT B

 

WARRANT TO PURCHASE STOCK

 

Company: VG Life Sciences,
Inc.

Number of Shares: 200,000

Class of Stock: Common

Initial Exercise Price Per Share: $0.45

Issue Date: May 14, 2015

 

THIS
WARRANT CERTIFIES THAT, for the agreed upon value of $1.00 and for other good and valuable consideration, Hock Tiam Tay, (“Holder”)
is entitled to purchase the number of fully paid and nonassessable shares of the class of securities (the “Shares”)
of VG Life Sciences, Inc. (the “Company” or “VGLS”) at the initial exercise price per Share (the “Warrant
Price”) all as set forth above and as adjusted pursuant to Article 2 of this Warrant, subject to the provisions and upon
the terms and conditions set forth of this Warrant.

 

ARTICLE 1. EXERCISE

 

1.1          Method
of Exercise. Holder may exercise this Warrant by delivering a duly executed Notice of Exercise in substantially the form attached
as Appendix 1 to the principal office of the Company. Unless Holder is exercising the conversion right set forth in Section 1.2,
Holders shall also deliver to the Company a check for the aggregate Warrant Price for the Shares being purchased.

 

1.2          Conversion
Right. In lieu of exercising this Warrant as specified in Section 1.1, Holder may from time to time convert this Warrant,
in whole or in part, into a number of Shares determined by dividing (a) the aggregate fair market value of the Shares or other
securities otherwise issuable upon exercise of this Warrant minus the aggregate Warrant Price of such Shares by (b) the fair market
value of one Share. The fair market value of the Shares shall be determined pursuant Section 1.4.

 

1.3          No
Rights Shareholder. This Warrant does not entitle Holder to any voting rights as a shareholder of the company prior to the
exercise hereof.

 

1.4          Fair
Market Value. For purposes of Section 1.2, if the Shares are traded in a public market, the fair market value of the Shares
shall be the closing price of the Shares (or the closing price of the Company’s stock into which the Shares are convertible)
reported for the business day immediately before Holder delivers its Notice of Exercise to the Company. If the Shares are not
traded in a public market, the Board of Directors of the Company shall determine fair market value in its reasonable good faith
judgment. The foregoing notwithstanding, if Holder advises the Board of Directors in writing that Holder disagrees with such determination,
then the Company and Holder shall promptly agree upon a reputable investment banking or public accounting firm to undertake such
valuation. If the valuation of such investment banking firm is greater than that determined by the Board of Directors, then all
fees and expenses of such investment banking firm shall be paid by the company. In all other circumstances, such fees and expenses
shall be paid by Holder.

 

    	17

    	 

    

 

1.5          Delivery
of Certificate and New Warrant. Promptly after Holder exercises or converts this Warrant, the Company shall deliver to Holder
certificates for the Shares acquired and, if this Warrant has not been fully exercised or converted and has not been fully exercised
or converted and has not expired, a new Warrant representing the Shares not so acquired.

 

1.6          Replacement
of Warrants. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of
this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in
form and amount to the Company or, in the case of mutilation, or surrender and cancellation of this Warrant, the Company at its
expense shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor.

 

1.7          Repurchase
on Sale, Merger, or Consolidation of the Company

 

1.7.1 
“Acquisition”  For the purpose of this Warrant, “Acquisition” means (a) the closing of the sale, transfer
or other disposition of all or substantially all of the VGLS’s assets, (b) the consummation of the merger or consolidation
of VGLS with or into another entity (except a merger or consolidation in which the holders of capital stock of VGLS immediately
prior to such merger or consolidation continue to hold at least fifty percent (50%) of the voting power of the capital stock of
VGLS or the surviving or acquiring entity), or any transaction or series of transactions to which VGLS is a party in which in excess
of fifty percent (50%) of VGLS’s voting power is transferred, or (c) the exclusive license of all or substantially all of
the intellectual property of VGLS to a third party.

 

1.7.2 Assumption
of Warrant. Upon the closing of any Acquisition the successor entity shall assume the obligations of this Warrant, and this
Warrant shall be exercisable for the same securities, cash, and property as would be payable for the Shares issuable upon exercise
of the unexercised portion of this Warrant as if such Shares were outstanding on the record date for the Acquisition and subsequent
closing. The Warrant Price shall be adjusted accordingly.

 

1.7.3 Purchase
Right. Notwithstanding the foregoing, at the election of Holder, the Company shall purchase the unexercised portion of this
Warrant for cash upon the closing of any Acquisition for an amount equal to (a) the fair market value of any consideration that
would have been received by Holder in consideration of the Shares had Holder exercised the unexercised portion of this Warrant
immediately before the record date for determining the shareholders entitled to participate in the proceeds of the Acquisition,
less (b) the aggregate Warrant Price of the Shares, but in no event less than zero.

 

    	18

    	 

    

 

ARTICLE 2. ADJUSTMENTS TO THE SHARES.

 

2.1          Stock
Dividends, Splits, Etc. If the Company declares or pays a dividend on its common stock (or the Shares if the Shares are
securities other than common stock ) payable in common stock, or other securities, subdivides the outstanding common stock
into a greater amount of common stock, or, if the Shares are securities other than common stock, subdivides the Shares in a
transaction that increases the amount of common stock into which the Shares are convertible, then upon exercise of this
Warrant, for each Share acquired, Holder shall receive, without cost to Holder, the total number and kind of securities to
which Holder would have been entitled had Holder owned the Shares of record as of the date the dividend or subdivision
occurred.

 

2.2          Reclassification,
Exchange or Substitution. Upon any reclassification, exchange, substitution, or other event that results in a change of the
number and/or class of the securities issuable upon exercise or conversion of this Warrant, Holder shall be entitled to receive,
upon exercise or conversion of this Warrant, the number and kind of securities and property that Holder would have received for
the shares if this Warrant had been exercised immediately before such reclassification, exchange, substitution, or other event.
Such an event shall include any automatic conversion of the outstanding or issuable securities of the Company of the same class
or series as the Shares to common stock pursuant to the terms of the Company’s Certificate of Incorporation upon the closing
of a registered public offering of the Company’s common stock. The Company or its successor shall promptly issue to Holder
a new Warrant for such new securities or other property. The new adjustments provided for in this Article 2 including, without
limitation, adjustments to the Warrant Price and to the number of securities or property issuable upon exercise of the new Warrant.
The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, substitutions, or other events.

 

2.3          Adjustments
for Combinations, Etc. If the outstanding Shares are combined or consolidated, by reclassification or otherwise, into a lesser
number of shares, the Warrant price shall be proportionately increased.

 

2.4          Adjustments
for Diluting Issuances. The number of shares of common stock issuable upon conversion of the Shares, shall be subject to adjustment,
from time to time in the manner set forth in the Company’s Certificate of Incorporation with respect to issuance of securities
for a price lower than certain prices specified in the Certificate of Incorporation.

 

2.5          No
Impairment. The Company shall not, by amendment of its Certificate of Incorporation or through a reorganization, transfer
of assets, consolidation, merger, dissolution, issue, or sale of securities or any other voluntary action, avoid or seek to avoid
the observance or performance of any of the terms to be observed or performed under this Warrant by the Company, but shall at
all times in good faith assist in carrying out of all the provisions of this Article 2 and in taking all such action as may be
necessary or appropriate to protect Holder’s rights under this Article against impairment. If the Company takes any action
affecting the Shares or its common stock other than as described above that adversely affects Holder’s rights under this
Warrant, the Warrant Price shall be adjusted downward and the number of Shares issuable upon exercise of this Warrant shall be
adjusted upward in such a manner that the aggregate Warrant price of this Warrant is unchanged.

 

2.6          Fractional
Shares.  No fractional Shares shall be issuable upon exercise or conversion of the Warrant and the number of Shares to
be issued shall be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise or
conversion of the Warrant, the Company shall eliminate such fractional share interest by paying Holder amount computed by
multiplying the fractional interest by the fair market value of a full Share.

 

    	19

    	 

    

 

2.7          Certificate
as to Adjustments. Upon each adjustment of the Warrant Price, the Company at its expense shall promptly compute such
adjustment, and furnish Holder with a certificate of its Chief Financial officer setting forth such adjustment and the facts
upon which such adjustment is based. The Company shall, upon written request, furnish Holder a certificate setting forth the
Warrant price in effect upon the date thereof and the series of adjustments leading to such Warrant Price.

 

ARTICLE 3. REPRESENTATIONS
AND COVENANTS OF THE COMPANY.

 

3.1          Representations
and Warranties. The Company hereby represents and warrants to the Holder that all Shares which may be issued upon the exercise
of the purchase right represented by this Warrant and all securities, if any, issuable upon conversion of the Shares, shall, upon
issuance, be duly authorized, validly issued, fully paid and nonassessable, and free of any liens and encumbrances except for
restrictions on transfer provided for herein or under applicable federal and state securities laws.

 

3.2          Notice
of Certain Events. If the company proposes at any time (a) to declare any dividend or distribution upon its common stock,
whether in cash, property, stock or other securities and whether or not a regular cash dividend; (b) to offer for subscription
pro rata to the holders of any class or series or other rights; (c) to effect any reclassification or recapitalization of common
stock; (d) to merge or consolidate with or into any other corporation, or sell, lease, license, or convey all or substantially
all of its assets, or to liquidate, dissolve or wind up; or (e) offer holders of registration rights the opportunity to participate
in an underwritten public offering of the company’s securities for cash, then, in connection with each such event, the Company
shall give Holder (1) at least 20 days prior written notice of the date on which a record will be taken for such dividend, distribution
or subscription rights (and specifying the date on which the holders of common stock will be entitled thereto) or for determining
rights to vote, if any, in respect of the matters referred to in (c) and (d) above; 2 in the case of the matters referred to in
(c) and (d) above at least 20 days prior written notice of the date when the same will take place (and specifying the date on
which the holders of common stock will be entitled to exchange their common stock for securities or other property deliverable
upon the occurrence of such event); and (3) in the case of the matter referred to in (e) above, the same notice as is given to
the holders of such registration rights.

 

3.3          Information
Rights. So long as the Holder holds this Warrant and /or any of the Shares, the Company shall deliver to the Holder (a) promptly
after mailing, copies of all notices or other written communications to the shareholders of the Company, (b) within ninety (90)
days after the end of each fiscal year of the Company, the annual financial statements of the Company.

 

3.4          Registration
Under Securities Act of 1933, as amended.  The Company agrees that the Shares shall be subject to the registration rights
granted to any other holders of the Company’s common stock.

 

    	20

    	 

    

 

ARTICLE 4. MISCELLANEOUS.

 

4.1          Term.
This Warrant is exercisable, in whole or in part, at any time and from time to time on or after the fourth anniversary of the Issue
Date hereof and up to and including the fifth anniversary of the Issue Date.

 

4.2          Legends. This Warrant and the Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any)
shall be imprinted with a legend in substantially the following form:

 

THIS SECURITY HAS NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION
THEREOF UNDER SUCH ACT OR PURSUANT TO RULE 144 OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE CORPORATION AND ITS COUNSEL
THAT SUCH REGISTRATION IS NOT REQUIRED.

 

4.3          Compliance
with Securities Laws on Transfer. This Warrant and the Shares issuable upon exercise this Warrant (and the securities issuable
, directly or indirectly, upon conversion of the shares, if any) may not be transferred or assigned in whole or in part without
compliance with limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the
Company, as reasonable requested by the Company). The Company shall not require Holder to provide an opinion of counsel if the
transfer is to an affiliate of Holder or if there is no material question as to the availability of current information as referenced
in rule 144(c), Holder represents that it has complied with Rule 144(d) and (e) in reasonable detail, the selling broker represents
that it has complied with Rule 144(f), and the Company is provided with a copy of Holder’s notice of proposed sale.

 

4.4          Transfer
Procedure. Subject to the provisions of Section 4.2, Holder may transfer all or part of this Warrant or the Shares issuable
upon exercise of this Warrant (or the securities issuable, directly or indirectly, upon conversion of the Shares, if any) by giving
the Company notice of the portion of the Warrant being transferred setting forth the name, address and taxpayer identification
number of the transferee and surrendering this Warrant to the company for reissuance to the transferee(s) (and Holder if applicable).

 

4.5          Notices.
All notices and other communications from the Company to the Holder, or vice versa, shall be deemed delivered and effective
when given personally or mailed by first- class registered or certified mail, postage prepaid, at such address as may have
been furnished to the Company or the Holder, as the case may be, in writing by the Company or such holder from time to
time.

 

    	21

    	 

    

 

4.6          Waiver.
This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the
party against which enforcement of such change, waiver, discharge or termination is sought.

 

4.7          Attorneys
Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant , the party prevailing
in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorney’s
fees.

 

4.8          Governing
Law. This Warrant shall be governed by and construed in accordance with the laws of the State of California, without giving
effect to its principles regarding conflicts of law.

 

 

 

 

____________________________

By: John P. Tynan

Title: President & CEO

 

    	22

    	 

    

 

APPENDIX 1

 

 

 

NOTICE OF EXERCISE

 

 

 

 

1.          The
undersigned hereby elects to convert the attached Warrant into in the manner specified in the Warrant. This conversion is exercised
with respect to ____________ of the Shares covered by the Warrant.

 

 

 

 

2.          Please issue a certificate
or certificates representing said shares in the name of the undersigned or in such other name as is specified below:

 

 

__________________________________

(Name)

 

__________________________________

 

__________________________________

(Address)

 

3.          The undersigned
represents it is acquiring the shares solely for its own account and not as a nominee for any other party and not with a view toward
the resale or distribution thereof except in compliance with applicable securities laws.

 

	__________________________________	__________________________________
	(Date)	(Signature)
	 	 

 

 

    	23

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}]]